home / stock / alpmy / alpmy news

ALPMY News and Press, Astellas Pharma Inc. ADR From 12/18/19

Stock Information
Company Name: Astellas Pharma Inc. ADR
Stock Symbol: ALPMY
Market: OTC
Menu
ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board
Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...
ALPMY - FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV(TM) (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

TOKYO and BOTHELL, Wash. , Dec. 18, 2019 /PRNewswire/ --  Astellas Pharma Inc.   (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc.   (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) granted ...
ALPMY - XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

NEW YORK and TOKYO , Dec. 16, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application ...

ALPMY - Kinase inhibitors in focus on after Merck bid for ArQule

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

ALPMY - Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science

MENLO PARK, Calif. , Dec. 5, 2019 /PRNewswire/ -- Astellas Venture Management (President: Shunichiro Matsumoto , Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas"), and Mission Bay...
ALPMY - Here's Why uniQure Is Rallying 13% Today

After big biopharma Astellas   (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...

ALPMY - Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

TOKYO , Dec. 2, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at the 61 st American Society of Hematology (ASH) Annual Meeting, taking place Dec. ...

ALPMY - Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

BOTHELL, Wash. , and TOKYO , Dec. 2, 2019 /PRNewswire/ --  Seattle Genetics, Inc.  (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas"), today announced a clinical collaboration agreement with Merck, known as MSD outside ...
ALPMY - Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)

TOKYO , Nov. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that the China National Medical Products Administration (NMPA) approved a new drug application (NDA) for XTANDI ® (enzalutamide) on No...

ALPMY - Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics

TOKYO and COLUMBIA, Md. , Nov. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas" ) and Welldoc, Inc. (President, CEO: Kevin McRaith , "Welldoc") today announced that the companies have entered into a collaboration a...

ALPMY - Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
Previous 10 Next 10